Page 4 - Next Test News Today

Guardant Health (NASDAQ:GH – Free Report) had its target price cut by Morgan Stanley from $55.00 to $50.00 in a research report report published on Wednesday morning, Benzinga reports. They currently have an overweight rating on the stock. GH has been the subject of a number of other research reports. The Goldman Sachs Group dropped […]

Mackenzie Financial Corp acquired a new stake in Guardant Health, Inc. (NASDAQ:GH – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 6,978 shares of the company’s stock, valued at approximately $247,000. Several other hedge funds have also recently bought and sold shares […]

Guardant Health (NASDAQ:GH – Free Report) had its price objective cut by Morgan Stanley from $55.00 to $50.00 in a report released on Wednesday, Benzinga reports. They currently have an overweight rating on the stock. Several other research firms have also weighed in on GH. Citigroup reiterated a buy rating and issued a $50.00 price […]

Bfsg LLC bought a new stake in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 22,676 shares of the company’s stock, valued at approximately $812,000. Other hedge funds and other institutional investors […]

Shares of Guardant Health, Inc. (NASDAQ:GH – Get Free Report) have received a consensus recommendation of “Buy” from the fourteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. Fourteen research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have covered the stock in […]

Sanford C. Bernstein started coverage on shares of Guardant Health (NASDAQ:GH – Free Report) in a report released on Thursday, Marketbeat reports. The brokerage issued an outperform rating and a $34.00 target price on the stock. Several other equities analysts have also recently commented on GH. William Blair reissued an outperform rating on shares of […]

Guardant Health (NASDAQ:GH – Get Free Report)‘s stock had its “buy” rating reissued by Citigroup in a research note issued on Monday, Benzinga reports. They currently have a $50.00 target price on the stock. Citigroup’s price target would suggest a potential upside of 72.24% from the company’s current price. Several other equities research analysts have […]

William Blair reiterated their outperform rating on shares of Guardant Health (NASDAQ:GH – Free Report) in a research report sent to investors on Friday, Marketbeat Ratings reports. Other equities analysts also recently issued research reports about the company. Citigroup boosted their target price on Guardant Health from $40.00 to $50.00 and gave the company a […]

Aristotle Atlantic Partners LLC raised its position in Guardant Health, Inc. (NASDAQ:GH – Free Report) by 0.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 620,494 shares of the company’s stock after purchasing an additional 1,723 shares during the period. Aristotle Atlantic Partners LLC […]

Guardant Health (NASDAQ:GH – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at William Blair in a research note issued to investors on Friday, RTT News reports. Several other research firms also recently weighed in on GH. Citigroup upped their price objective on shares of Guardant Health from $40.00 to $50.00 […]